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PennsylvaniaClinical trials testing infertility treatments often do not report on the major outcomes of interest to patients and clinicians and the public
(such as live birth) nor on the harms, including maternal risks during pregnancy and fetal anomalies. This is complicated by the multiple
participants in infertility trials which may include a woman (mother), a man (father), and a third individual if successful, their offspring
(child), who is also the desired outcome of treatment. The primary outcome of interest and many adverse events occur after cessation of
infertility treatment and during pregnancy and the puerperium, which creates a unique burden of follow-up for clinical trial investi-
gators and participants. In 2013, because of the inconsistencies in trial reporting and the unique aspects of infertility trials not
adequately addressed by existing Consolidated Standards of Reporting Trials (CONSORT) statements, we convened a consensus confer-
ence in Harbin, China, with the aim of planning modiﬁcations to the CONSORT checklist to improve the quality of reporting of clinical
trials testing infertility treatment. The consensus group recommended that the preferred primary outcome of all infertility trials is live
birth (deﬁned as any delivery of a live infant afterR20 weeks' gestation) or cumulative live birth, deﬁned as the live birth per women
over a deﬁned time period (or number of treatment cycles). In addition, harms to all participants should be systematically collected and
reported, including during the intervention, any resulting pregnancy, and the neonatal period. Routine information should be collected
and reported on both male and female participants in the trial. We propose to track the change in quality that these guidelines mayUse your smartphoneproduce in published trials testing infertility treatments. Our ultimate goal is to increase the
transparency of beneﬁts and risks of infertility treatments to provide better medical care to
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Fertility and Sterility®contributes to incomplete reporting of outcomes and harms of
treatment. Clinical trials in infertility frequently do not report
items of critical importance regarding efﬁcacy, such as
ongoing pregnancy (3, 4) or live birth of a healthy infant,
arguably the most important event (5). Rather, they often
focus on surrogate outcomes of varying clinical importance,
such as ovulation rates, number of oocytes retrieved embryo,
and fertilization and implantation rates (6, 7). Reports on the
safety of interventions include risks to women and men
during infertility treatment, to the mother during the
subsequent pregnancy, and to fetuses and infants, including
preterm delivery. In addition, fetal anomaly rates,
developmental delays and other adverse infant outcomes (8)
are variably reported or not mentioned at all (4). This creates
uncertainty on how long to report outcomes and harms in
humans after completion of the infertility intervention (9).
We sought to improve the quality of reporting of
infertility trials by convening an expert conference of key
stakeholders in the conduct and publishing of infertility trials
to consider how to improve publication by including items of
vital interest to infertile couples, clinicians, and the public.
We achieved a consensus on these items and drafted changes
to the 22-item checklist of the CONSORT statement to provide
guidance on what to collect on whom and for how long in
infertility trials. Such guidance has already been achieved
for other specialized types of clinical trials (10, 11, 12, 13).METHODS
We developed these changes in three phases, including a pre-
meeting planning phase, the meeting itself, and a post-meeting
review of results based on previous extensions to the CONSORT
checklist (10, 11, 12) and published guidance for implementing
such change (14). In planning for the meeting, we sought to
assemble a representative group of experienced investigators
in trials of infertility treatments as well as the editors of the
leading journals that publish fertility trials, Fertility and
Sterility and Human Reproduction, to participate in the
meeting. With the input of the Scientiﬁc Committee we framed
topics of relevance to clinical trials of infertility, and most
invited participants were asked to prepare a lecture in their
ﬁeld of expertise for the open part of the meeting.
Invited participants included experts in reproductive med-
icine and reproductive endocrinology, andrology, maternal-
fetal medicine, neonatology, traditional Chinese medicine,
biostatistics and clinical trial study design, data safety moni-
toring, and journal editors. Invited participants (n ¼ 25) were
queried by e-mail before the meeting about their suggested
changes to the CONSORT checklist. We received comments
from 11 individuals in the following distribution according to
the checklist item (in descending order of frequency): Results
(22 comments), Intervention (10 comments), Outcomes (9 com-
ments), Introduction (6 comments), Title and Abstract (5 com-
ments), Discussion (5 comments), Participants (3 comments),
Sample size (4 comments), Blinding (2 comments), Statistical
methods (4 comments), Randomization (3 comments), Other
information (3 comments), and Methods (2 comments).
The meeting was designed as a 1.5-day open meeting
with public lectures framing issues in infertility trials fol-VOL. 102 NO. 4 / OCTOBER 2014lowed by a 1.5-day closed meeting among the invited partic-
ipants to achieve consensus. The Scientiﬁc Committee divided
the three half-day closed sessions into discussions about:
1) Main outcomes of infertility trials: 2) Adverse events in
infertility trials; and 3) Participant issues in infertility trials.
Each session was led by two members of the Scientiﬁc Com-
mittee, and each suggested modiﬁcation was discussed until
consensus was achieved, with a ﬁnal total of 20 modiﬁcations
(n ¼ 20). Representatives from the National Institutes of
Health of the United States were unable to attend the meeting
owing to budgetary sequestration, and one representative
from China was unable to attend the closed meeting. After
the meeting we circulated a draft summary report to all par-
ticipants to ensure that it accurately represented the deliber-
ations and decisions of the consensus group.
RESULTS
The group recommended a revision to eight items in the CON-
SORT Checklist (Table 1). The full amended CONSORT check-
list is shown in Table 2. Several of the revisions had multiple
components. The item that generated the most discussion was
the optimal primary outcome of an infertility trial with
options ranging from an ongoing viable intrauterine preg-
nancy to a healthy child with normal development. The group
decided that trials testing infertility treatments should report
as the primary outcome live birth with a deﬁnition based on
gestational age (i.e.,R20 weeks) reﬂecting the World Health
Organization deﬁnition of live birth as a fetus exiting the
body displaying signs of life, such as movement, breathing,
or heart beat (15). Although the group acknowledged that
the ultimate goal of an infertility trial is a healthy baby who
develops normally, and that ideally this outcome should
always be reported, the difﬁculties in tracking this outcome
and clearly deﬁning it precluded it as a choice for the primary
outcome of an infertility trial. Because most infertility trials
involve multiple treatment cycles, cumulative live birth rates
should also be reported in this context.
This discussion also overlapped with the potential harms
of infertility treatment. The group recommended more com-
plete tracking of potential harms of infertility treatment,
including ovarian hyperstimulation syndrome and multiple
pregnancy, as well as adverse events during pregnancy and
the neonatal/infancy period, including any fetal anomalies.
To aid reporting of such events, the group developed a table
of key potential harms to collect and report (Table 3)
DISCUSSION
We developed recommendations for modiﬁcations of the
CONSORT checklist to improve the quality of reporting of
trials of infertility treatments. Our suggested revisions were
designed to aid transparency of trials, including requiring
more complete characterization of the participants in an
infertility trial, providing some uniform measure of preg-
nancy outcome (we chose live birth), and accounting for the
major harms and risks to the participants in an infertility trial
as well as the resulting fetus(es)/infant(s). Although we see
this checklist primarily of relevance to larger pragmatic
randomized infertility trials, we think it is also applicable953
TABLE 1
Summary of proposed modiﬁcations for infertility trials to the Consolidated Standards of Reporting Trials (CONSORT) 2010 Statement (only items with modiﬁcations are included here; the full
checklist is shown in Table 2).
Section Topic Item no. Current description Consensus modiﬁcation
Participants 4a Eligibility criteria for participants Characterize how infertility factors in male and female participants were
evaluated, describe the deﬁnitions used, any preconception
screening, and from which participants informed consents were
obtained.
Interventions 5 The interventions for each group with sufﬁcient details to allow
replication, including how and when they were actually administered
State the duration of the intervention noting when the treatment started
and concluded. State the temporal relation of the intervention
to randomization and pregnancy.
Outcomes 6a Completely deﬁned prespeciﬁed primary and secondary outcome
measures, including how and when they were assessed
Clearly deﬁne the primary outcome. Reporting live birth (deﬁned as a
delivery afterR20 weeks' gestation) is preferred (including
gestational age, birthweight, and sex of infant).
When more than one cycle occurs or frozen embryos are transferred,
the preferred outcome is cumulative live birth per woman.
Secondary pregnancy outcomes that merit reporting are serum
pregnancy, ongoing pregnancy (R12 weeks), multiple pregnancy,
and an accounting of all pregnancy losses.
Both male and female outcomes, other than live birth, could be
the primary outcome and should be justiﬁed. When live birth is not
the primary end point and infertility treatment is given (for example,
embryos are transferred), live birth should still be reported.
Results Participant ﬂow 13a For each group, the numbers of participants who were randomly
assigned, received intended treatment, and were analyzed
for the primary outcome
Report the numbers of couples who were screened and eligible.
Baseline data 15 A table showing baseline demographic and clinical characteristics
for each group
State the duration of infertility (including whether it is primary or
secondary), relevant obstetrical history, and cause of infertility
in women and men.
Numbers analyzed 16 For each group, number of participants (denominator) included in each
analysis and whether the analysis was by original assigned groups
The preferred unit of analysis is per randomized individual/couple (not
cycles or oocytes/embryos) for a speciﬁed period of time (preferably
displayedwith life table analysis). If per-cycle analysis is used, it should
be justiﬁed andmust account for individuals receivingmultiple cycles.
Clearly describewhat happens to all multiple pregnancies, including fetal
reduction and vanishing gestations. Report multiple pregnancy
outcome both per woman and per pregnancy. Separate out
twin/triplets/quads/etc.
Harms 19 All important harms or unintended effects in each group (for speciﬁc
guidance, see CONSORT for harms, (7)
Report all important harms or unintended effects in each group (men,
women, infants) during treatment (including both male and female
partners), during pregnancy, and around birth, and in infants after
birth.
Reportable harms include ovarian hyperstimulation syndrome, infection,
bleeding, multiple pregnancy (see also item 16) and maternal
pregnancy complications, and harms or unintended effects on the
fetus/newborn, including congenital abnormalities, and major
neonatal complications as well as infant developmental delays
or medical problems.
Discussion Interpretation 22 Interpretation consistent with results, balancing beneﬁts and harms, and
considering other relevant evidence
Balance outcomes and any competing interests of female and male
participants and infant.
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TABLE 2
2014 checklist of information to include when reporting a randomized trial of infertility treatment.a
Section/topic Item no. Checklist item
Reported
on page no.
Title and abstract
1a Identiﬁcation as a randomized trial in the title
1b Structured summary of trial design, methods, results, and conclusions (for speciﬁc guidance see CONSORT
for abstracts)
Introduction
Background and objectives 2a Scientiﬁc background and explanation of rationale
2b Speciﬁc objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons
Participants 4a Eligibility criteria for participants.
Characterize how infertility factors in male and female participants were evaluated; describe the deﬁnitions
used, any preconception screening, and from which participants informed consents were obtained.
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufﬁcient details to allow replication, including how and when they
were actually administered.
(State the duration of the intervention noting when the treatment started and concluded. State the temporal
relation of the intervention to randomization and pregnancy.)
Outcomes 6a Completely deﬁned prespeciﬁed primary and secondary outcome measures, including how and when they
were assessed.
Clearly deﬁne the primary outcome. Reporting live birth (deﬁned as a
delivery afterR20 weeks' gestation) is preferred (including gestational age, birthweight, and sex of
infant). For infertility trials, wheremore than one cycle occurs or where frozen embryos are transferred, the
preferred outcome is cumulative live birth per woman. Secondary pregnancy outcomes that merit
reporting are serumpregnancy, ongoing pregnancy (R12weeks), multiple pregnancy, and an accounting
of all pregnancy losses.
Both male and female outcomes, other than live birth, could be the primary outcome and should be justiﬁed.
When live birth is not the primary end point and infertility treatment is given (e.g., embryos are
transferred), live birth should still be reported.
6b Any changes to trial outcomes after the trial commenced, with reasons
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim analyses and stopping guidelines
Randomization
Sequence generation 8a Method used to generate the random allocation sequence
8b Type of randomization; details of any restriction (such as blocking and block size)
Allocation concealment mechanism 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers),
describing any steps taken to conceal the sequence until interventions were assigned
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants
to interventions
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those
assessing outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses
Results
Harbin Consensus Conference Workshop Group. Modifying the reporting statement for infertility trials. Fertil Steril 2014.
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TABLE 2
Continued.
Section/topic Item no. Checklist item
Reported
on page no.
Title and abstract
Participant ﬂow (a diagram is strongly recommended) 13a For each group, the numbers of participants who were randomly assign , received intended treatment, and
were analyzed for the primary outcome.
Report the numbers of couples who were screened and eligible.
13b For each group, losses and exclusions after randomization, together w reasons
Recruitment 14a Dates deﬁning the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinical characteristics for e h group.
State the duration of infertility (including whether it is primary or secon ry), relevant obstetrical history,
and cause of infertility in women and men if possible.
Numbers analyzed 16 For each group, number of participants (denominator) included in each a lysis and whether the analysis was
by original assigned groups.
The preferred unit of analysis is per randomized individual/couple (not les or oocytes/embryos) for a
speciﬁed period of time (preferably displayed with life table analysis) per-cycle analysis is used, it should
be justiﬁed andmust account for individuals receivingmultiple cycles learly describe what happens to all
multiple pregnancies, including fetal reduction and vanishing gesta ns. Report multiple pregnancy
outcome both per woman and per pregnancy. Separate out twin/tr lets/quads/etc.
Outcomes and estimation 17a For each primary and secondary outcome, results for each group, and estimated effect size and its
precision (such as 95% conﬁdence interval)
17b For binary outcomes, presentation of both absolute and relative effect es is recommended
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses a adjusted analyses, distinguishing
prespeciﬁed from exploratory
Harms 19 All important harms or unintended effects in each group (for speciﬁc g ance see CONSORT for harms)
Report all important harms or unintended effects in each group (males emales, infants); during treatment
(including both male and female partners), during pregnancy, and ar nd birth, and in infants after birth.
Reportable harms include ovarian hyperstimulation syndrome, infec n, bleeding, multiple pregnancy
(see also item 16) and maternal pregnancy complications, and harm or unintended effects on the
fetus/newborn, including congenital abnormalities, and major neon al complications as well as infant
developmental delays or medical problems.
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, relevant, multiplicity of analyses
Generalizability 21 Generalizability (external validity, applicability) of the trial ﬁndings
Interpretation 22 Interpretation consistent with results, balancing beneﬁts and harms, and onsidering other relevant evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as supply of drugs), role of nders
a We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration, as well as the 2014 Harbin Consensus Document Explanation and Elaboration pplemental Material, (available online) for important clariﬁcations on
all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomized trials, noninferiority and equivalence trials, nonpharmacologic treatments, herbal interventions, an ragmatic trials. Additional extensions are forthcoming: For those and
for up-to-date references relevant to this checklist, see www.consort-statement.org.
Harbin Consensus Conference Workshop Group. Modifying the reporting statement for infertility trials. Fertil Steril 2014.
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TABLE 3
Potential harms to participants in an infertility trial that merit reporting.
Time Womena Mena Fetus/Infanta
Delivery of the infertility
intervention
Burden of treatment/stress,c
OHSS,b bleeding, infection,
adverse oocyte qualityc
Burden of treatment/stress,c
adverse semen qualityc
Pregnancy Multiple pregnancy, ectopic
pregnancy, pregnancy loss (all
trimesters), pregnancy-related
hypertension,d gestational
diabetes,e abnormal
placentation,f gestational
trophoblastic diseaseg
Adverse embryo quality,c fetal
anomaly, fetal growth
restriction (FGR)h
Delivery Cesearean section/operative
deliveries
Small or large for gestational age
(SGA/LGA),i preterm delivery
(PTD),j anomalies detected by
obstetrical screening
Postpartum and
neonatal/infancy
Thromboembolism, postpartum
depression, Lactation rates
Anomalies detected after birth,
neonatal intensive care unit
admission, length of stay
a A death of male or female parent or fetus/infant participating in trials should be reported.
b OHSS (ovarian hyperstimulation syndrome) is an exaggerated and symptomatic response to ovulation induction therapy (16).
c There are currently no accepted standards for determining these parameters.
d Pregnancy-related hypertension includes preeclampsia deﬁned as new-onset hypertension with proteinuria after 20 weeks' gestation, eclampsia deﬁned as the development of seizures in a
women with preeclampsia, and HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) (17).
e Gestational Diabetes has varying deﬁnitions depending on country of origin. The USA uses a two-step screening approach with a 1-hour 50-g oral glucose test followed by a 3-hour 100-g
oral glucose test (18), whereas most of the rest of the world uses a 2-hour 75-g oral glucose test (19).
f Abnormal placentation includes placentia previa, placental abruption, placenta accreta, increta, and percreta.
g Gestational trophoblastic disease includes hydatidiform mole (complete or partial), persistent/invasive gestational trophoblastic neoplasia, choriocarcinoma, and placental site trophoblastic
tumors.
h FGR is most commonly deﬁned as an ultrasound-determined estimated fetal weight below the 3rd percentile for gestational age (20).
i SGA is most commonly deﬁned as a weight below the 10th percentile for the gestational age. At term this is%2,500 g. LGA is most commonly deﬁned as a weight above the 10th percentile for
the gestational age. At term this isR4,000 g (21).
j PTD is deﬁned by a delivery before 37 weeks' gestation (22).
Harbin Consensus Conference Workshop Group. Modifying the reporting statement for infertility trials. Fertil Steril 2014.
Fertility and Sterility®to smaller randomized or prospective nonrandomized or
single-intervention trials that pilot newer treatments. All
such trials must be registered with a clinical trial registry
before enrolling the ﬁrst patient, so it is possible to a priori
capture these outcomes in the trial design. It is incumbent
on all researchers to capture harms and pregnancy outcomes
even in these smaller trials, because they may serve as the ba-
sis for larger multicenter trials or become incorporated in sys-
tematic reviews. Incomplete reporting contributes to gaps in
evidence-based infertility treatment (23).
A longer more detailed rationale paper of the suggested is
available online, which includes examples of ideal reporting
and serves as an Explanation and Elaboration paper (14). We
will scrutinize published trials of infertility treatments subse-
quently to determine if our modiﬁcations to the CONSORT
checklist have improved the quality of reported information
regarding participants, outcomes, and harms of treatment.
We also plan to reconvene a meeting within the next 5 years
to formally review our experience and the need for further
modiﬁcations or revisions to the CONSORT checklist. In the
interim, we hope that medical journals will endorse their use,
that clinical researchers will incorporate the collection of these
data into their trial design and reporting, and ultimately that
medical care will improve from the increased transparency of
the risk-beneﬁt ratio of infertility treatments (23).
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SUPPLEMENTAL MATERIALImproving the Reporting of Clinical
Trials of Infertility Treatment
(IMPRINT): explanation and
elaboration of the modiﬁcation of the
CONSORT statement
Harbin Consensus Conference Workshop Group
Department of Obstetrics and Gynecology, First Afﬁliated Hospital, Heilongjiang University of Chinese Medicine, People's
Republic of China; and Department of Obstetrics and Gynecology, Penn State College of Medicine, Hershey, PennsylvaniaInfertility is a common disability, and is listed by the World Health Organization as the ﬁfth leading serious disability among popula-
tions under the age of 60 years. Effective therapies exist, but evidence-based options are uncommon. Clinical trials in infertility treat-
ment lack uniform guidelines for reporting methodology and results. Clinical trials in infertility are unique in that they usually involve,
at minimum, two individuals whomay receive or participate in treatment, i.e., a woman and aman, and if treatment is successful, a third
individual is followed in the trial, i.e., an infant, who is also the desired outcome of the treatment. This tripartite involvement of three
unique humans in a clinical trial is unprecedented in other clinical trials, and the Consolidated Standards of Reporting Trials (CONSORT)
guidelines leave several areas of uncertainty regarding what to report with multiple individuals involved. Two of the individuals, the
woman seeking pregnancy and the infant, have been classiﬁed ethically as vulnerable populations requiring careful collection of all
adverse events, including congenital anomaly rates. Participants may experience varied risk and beneﬁt from the trial; for example,
multiple pregnancy may be desired by the father, feared by the mother, and fatal to the infant. The outcome of primary interest to par-
ticipants, i.e., a live birth, is separated from the actual treatment by 9 months and subject to confounding inﬂuences from other factors.
These myriad issues lead to incomplete and inconsistent reporting of results. We developed this modiﬁcation to the CONSORT statement,
which we describe and justify in this document, to report the items of vital interest to infertile couples, clinicians, and the public that
should be collected in an infertility trial.
Key Words: Infertility trial, CONSORT, IMPRINT, explanation, elaborationI nfertility affects 10%–15% ofwomen (90), and is a majordisability ranked by the World
Health Organization (WHO) as the ﬁfth
leading serious disability among popu-
lations under the age of 60 years (102).
As such, affected individuals are enti-
tled to treatment. An increasing propor-
tion of children throughout the world
are conceived through infertility
treatments. Clinical trials are needed
to identify the best and safest treat-
ments, as well as to avoid overutiliza-
tion of expensive and invasive
therapies or the choice of unnecessary
treatments (7, 35, 49). The CONSORTConference Chairs: Richard S. Legro (USA) and Xia
Barnhart (USA), Cynthia Farquhar (New Zealan
Ben Mol (Australia).
VOL. 102 NO. 4 / OCTOBER 2014(Consolidated Standards Of Reporting
Trials) statement was developed to
provide an evidence-based minimal
set of standards for reporting clinical
trials (5). The CONSORT statement is
an evolving document that is updated
with increasing experience and evi-
dence for modiﬁcations (87). Addition-
ally there have been multiple
extensions to address speciﬁc types of
trial designs, e.g., parallel-group de-
signs (70) and noninferiority and equiv-
alence trials (80), or interventions, e.g.,
nonpharmacologic treatments (11),
herbals (27), and acupuncture (61).
Other groups in obstetrics and gynecol-oke Wu (China). Scientiﬁc Committee: Kurt T.
d), Bart C. J. M. Fauser (the Netherlands), andogy have modiﬁed the CONSORT
Checklist for obstetrical trials (14).
Trials in infertility are unique, and
the existing CONSORT statement and
its modiﬁcations do not cover the exi-
gencies of these trials. These include
the participation of multiple subjects
in the same unit of intervention and
analysis. Natural fertility involves a
mother and a father. Infertility classi-
cally affects women as they bear chil-
dren, and they disproportionately bear
the burden of the diagnosis. However,
both men and women can experience
diseases that cause infertility, and oli-
gospermia may be the single most com-
mon cause of infertility (36). The
International Committee for Moni-
toring Assisted Reproductive Technol-
ogy (ICMART) and WHO have deﬁned959.e1
SUPPLEMENTAL MATERIALinfertility as ‘‘a disease of the reproductive system deﬁned by
the failure to achieve a clinical pregnancy after 12 months or
more of regular unprotected sexual intercourse’’ (103). Thus,
both men and women, with their unique reproductive sys-
tems, can receive a diagnosis of infertility.
When donor gametes or surrogate gestational carriers are
factored into the clinical trial equation, the number of poten-
tial participants increases the complexity of trial design and
trial reporting. Successful infertility treatment resulting in
conception and leading to the primary outcome of live birth
is often separated by up to 38 weeks (if the pregnancy goes
to the estimated date of conﬁnement). During the pregnancy
a number of medical conditions (e.g., the development of pre-
term labor or gestational hypertension) can inﬂuence the
birth of a healthy infant. Care is often passed on from repro-
ductive medicine specialists to other providers, including
obstetricians and midwives (mother and fetus) and pediatri-
cians (infant), complicating the follow-up and reporting of
adverse events and outcomes. Critical outcomes that are lost
by not following pregnancies to completion are later maternal
pregnancy complications and infant morbidities and mortal-
ity, including congenital anomalies.
There is no consensus on the primary outcome for trials of
infertility treatments, the reportable secondary outcomes, how
todocument adverse events, or evenonwhom to report adverse
events (there are, as noted, usually a father and amother, and if
successful a fetus/infant). Deﬁnitions for common conditions,
suchas clinical pregnancy or even live birth, vary. These factors
and the uncertainty of what to report likely contribute to the
incomplete reporting of outcomes and adverse effects of infer-
tility treatment (20, 42). The varied reporting of outcomes also
complicates performance and interpretation of systematic
reviews and meta-analyses of fertility treatments (42). There
have appropriately been calls to improve the conduct and
reporting of infertility trials (20, 42).
THE IMPRINT MODIFICATIONS TO THE
CONSORT STATEMENT
To improve the reporting of infertility trials, we convened a
conference (Improving the Reporting of Infertility Trials) in
Harbin, China, in August 2013 and drafted a modiﬁcation
of the CONSORT Checklist (Table 1). We detail our methodol-
ogy in our shorter summary statement (34), but we followed a
published guidance for statement modiﬁcation by the
CONSORT group in designing our conference and reporting
its recommendations (71). Speciﬁcally we modiﬁed sections
of the CONSORT Checklist relating to Participants (Item 4),
Interventions (item 5), Outcomes (item 6), Results (item 13),
Baseline Data (item 15), Numbers analyzed (item 16), Harms
(item 19), and Interpretation (item 22).
HOW TO USE THIS PAPER
This paper is intended as a companion paper to our shorter
summary statement that also presents our (87) Checklist mod-
iﬁcations. Our aim is to improve the quality of reporting from
clinical trials of infertility treatments. In the following
paragraphs, we provide an item-by-item discussion of each
suggested modiﬁcation, including a published example of a959.e2checklist item that we consider as a model, followed by a
detailed explanation for the inclusion of this modiﬁcation
in the CONSORT Checklist. Our examples are not intended
to highlight the quality of speciﬁc research or endorse the
ﬁndings of any individual trial, only to highlight that this
particular item was well reported in the publication of the
trial. We also acknowledge that many of the examples do
not fully comply with our recommendations, but may repre-
sent only the best available alternative.TERMINOLOGY OF INFERTILITY
Wedid not reach a clear consensus onwhat to label the disorder
and its treatment. Infertility is an absolute diagnosis, and obvi-
ously many couples having regular intercourse conceive after
more than 12 months of unprotected sexual intercourse (18,
90). Therefore it is unfair to label what may be a spontaneous
remitting condition with an absolute term, analogous to
favoring ‘‘primary ovarian insufﬁciency’’ over ‘‘premature
ovarian failure.’’ Therefore many investigators have preferred
the term subfertility, and to describe treatments of the
condition as ‘‘fertility treatments.’’
We rely here on the decision of WHO to identify infertility
(and not subfertility) as a disability and therefore entitled to
medical treatment as a landmark step in the medical recogni-
tion of this disorder (102). Treatment is provided for a medical
disorder, e.g., acquired immune deﬁciency syndrome (AIDS)
treatment for AIDS, cancer treatment for cancer, asthma treat-
ment for asthma. Therefore we focus in this Explanation and
Elaboration document on infertility treatments that are pro-
vided within the context of infertility trials. We have entitled
our CONSORT modiﬁcation (with acronym) as: Improving the
Reporting of Clinical Trials of Infertility Treatment (IMPRINT).
Although the preference for a certain term is largely a semantic
issue, wewish to acknowledge that nomenclature is a potential
issue to address in future modiﬁcations of this statement.THE ITEMS
Section/Topic: Methods
Item no. 4a: eligibility criteria for participants. Modiﬁed
checklist item: Characterize how infertility factors in the
couple/participants were evaluated, what deﬁnitions were
used, any preconception screening, and if informed consents
were obtained from participating partners.
Example: Characterization of infertility in couple/partici-
pants. ‘‘All couples in which the woman was 21–39 years
old and who sought care for unexplained infertility at Boston
IVF or Harvard Vanguard Medical Associates were screened.
Eligibility criteria included 12 months of attempted concep-
tion; at least one ovary and ipsilateral patent fallopian tube
conﬁrmed by hysterosalpingogram or laparoscopy; and no
pelvic pathology, ectopic pregnancy, or previous infertility
treatment (with the exception of up to three cycles of clomi-
phene without IUI). Sufﬁcient ovarian reserve, demonstrated
by cycle day 3 FSH and estradiol values of <15 mIU/mL
and <100 pg/mL, respectively, and a sperm concentration
ofR15 million/mL or total motile sperm orR5 million total
motile sperm at reﬂex IUI preparation were required.VOL. 102 NO. 4 / OCTOBER 2014
TABLE 1
Summary of proposed modiﬁcations for infertility trials to the Consolidated Standards of Reporting Trials (CONSORT) 2010 Statement (only
items with modiﬁcations are included here; the full checklist is shown in Table 2).
Section Topic Item no. Current description Consensus modiﬁcation
Participants 4a Eligibility criteria for participants Characterize how infertility factors in male and
female participants were evaluated, describe the
deﬁnitions used, any preconception screening,
and from which participants informed consents
were obtained.
Interventions 5 The interventions for each group with
sufﬁcient details to allow replication,
including how and when they were
actually administered
State the duration of the intervention noting when
the treatment started and concluded. State the
temporal relation of the intervention to
randomization and pregnancy.
Outcomes 6a Completely deﬁned prespeciﬁed primary
and secondary outcome measures,
including how and when they were
assessed
Clearly deﬁne the primary outcome. Reporting live
birth (deﬁned as a delivery afterR20 weeks'
gestation) is preferred (including gestational age,
birthweight, and sex of infant).
When more than one cycle occurs or frozen
embryos are transferred, the preferred outcome
is cumulative live birth per woman.
Secondary pregnancy outcomes that merit
reporting are serum pregnancy, ongoing
pregnancy (R12 weeks), multiple pregnancy,
and an accounting of all pregnancy losses.
Both male and female outcomes, other than live
birth, could be the primary outcome and should
be justiﬁed. When live birth is not the primary
end point and infertility treatment is given (for
example, embryos are transferred), live birth
should still be reported.
Results Participant ﬂow 13a For each group, the numbers of
participants who were randomly
assigned, received intended treatment,
and were analyzed for the primary
outcome
Report the numbers of couples who were
screened and eligible.
Baseline data 15 A table showing baseline demographic
and clinical characteristics for
each group
State the duration of infertility (including whether it
is primary or secondary), relevant obstetrical
history, and cause of infertility in women and
men.
Numbers
analyzed
16 For each group, number of participants
(denominator) included in each analysis
and whether the analysis was by original
assigned groups
The preferred unit of analysis is per randomized
individual/couple (not cycles or oocytes/embryos)
for a speciﬁed period of time (preferably
displayed with life table analysis). If per-cycle
analysis is used, it should be justiﬁed and must
account for individuals receiving multiple cycles.
Clearly describe what happens to all multiple
pregnancies, including fetal reduction and
vanishing gestations. Report multiple pregnancy
outcome both per woman and per pregnancy.
Separate out twin/triplets/quads/etc.
Harms 19 All important harms or unintended effects
in each group (for speciﬁc guidance,
see CONSORT for harms, (56)
Report all important harms or unintended effects in
each group (men, women, infants) during
treatment (including both male and female
partners), during pregnancy, and around birth,
and in infants after birth.
Reportable harms include ovarian hyperstimulation
syndrome, infection, bleeding, multiple
pregnancy (see also item 16) and maternal
pregnancy complications, and harms or
unintended effects on the fetus/newborn,
including congenital abnormalities, and major
neonatal complications as well as infant
developmental delays or medical problems.
Discussion Interpretation 22 Interpretation consistent with results,
balancing beneﬁts and harms,
and considering other relevant evidence
Balance outcomes and any competing interests of
female and male participants and infant.
Harbin Consensus Conference Workshop Group. New reporting statement for infertility trials. Fertil Steril 2014.
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SUPPLEMENTAL MATERIALExclusion criteria included the presence of hydrosalpinges,
stage III or IV endometriosis, donor sperm, or the need for as-
sisted reproductive technique procedures other than IVF’’ (85).
Explanation. Because infertility trials often involve a
couple, full descriptions must be provided of the inclusion
and exclusion criteria for both male and female partners.
Age of the female and prior parity have consistently been
shown to be important predictors of infertility treatment
success (59). There are also other factors that may confound
interpretation of results if not accounted for or acknowl-
edged as a weakness, e.g., the presence of moderate to severe
undiagnosed endometriosis in women with unexplained
infertility. Furthermore, because there is debate about the
exact deﬁnition of many commonly used terms in reproduc-
tive medicine, such as polycystic ovary syndrome (PCOS) or
unexplained infertility, a full description should be provided
of the selection of participants such that clinicians and
researchers can apply the outcomes to their comparable
patient populations. Similarly, we recommend collecting
and reporting on key male fertility factors as a routine
part of any infertility trial.
Example: If informed consents were obtained from all par-
ticipants. ‘‘The protocol was approved by the local Institu-
tional Review Board at all sites, and participants (men and
women) all gave written informed consent’’ (54).
Explanation. Although clinical trials in infertility often pri-
marily focus on women, there are also many cases where
men are the primary focus of treatment, e.g., in the surgical
treatment of varicoceles (62). In either case, the partner is
often a coparticipant in the trial, the female for example,
agreeing to insemination or IVF/ICSI using her partner's
semen if there is oligospermia, or the male agreeing to regular
intercourse or to give a timed semen specimen speciﬁcally for
the purpose of achieving pregnancy in the female partner,
e.g., in the treatment of PCOS or unexplained infertility. There
is increasing awareness that partner consent is at times a
necessary component of reproductive research (1) and there-
fore investigators should report if both male and female part-
ners were separately consented for clinical trial participation.
Item no. 5: interventions. Modiﬁed checklist item: State the
duration of the intervention noting when the treatment
started and concluded in relation to randomization and preg-
nancy (if appropriate).
Example. ‘‘After providing written informed consent, the
women were randomly assigned to undergo three cycles of
IVF, with embryo selection based either on preimplantation
genetic screening or on morphologic features of the embryo;
the latter is standard care in the Netherlands. A cycle was
deﬁned as an ovarian stimulation procedure that resulted in
a follicular aspiration. Randomization was performed cen-
trally, before the ﬁrst follicular aspiration, by a computer pro-
gram with a minimization procedure for age (35 through
37 years and 38 through 41 years) and reproductive technique
(IVF and intracytoplasmic sperm injection), with stratiﬁcation
according to study center’’ (65).
Explanation. The duration of the intervention may be a spe-
ciﬁc period of time, e.g., weeks or months, which may be959.e4utilized for preconception lifestyle interventions. It may
also refer to a speciﬁc number of treatment cycles (as in
the above example), which can be of varying duration and
may also involve rest cycles between treatments. The dura-
tion by time and cycles should be clearly stated, as well as if
there were any inequalities in time or treatment cycles be-
tween randomization groups. The point of randomization
must be clearly identiﬁed in reference to treatment so the
potential for non–treatment-related pregnancies or selection
bias (e.g., excluding poor responders) can be assessed.
Pregnancies occurring before treatment initiation but after
randomization would be counted in an intention-to-treat
analysis in the randomized group, and therefore, to mini-
mize their impact on outcomes, pregnancy should be an
exclusion from randomization and, further, the time period
between randomization and treatment initiation should
be as brief as possible to avoid non–treatment-related
pregnancies.
Item no. 6: outcomes. Modiﬁed checklist item: Clearly
deﬁne the primary outcome. Reporting live birth (deﬁned as
a delivery afterR20 weeks' gestation) is preferred (including
gestational age, birthweight, and sex of infant).
When more than one cycle occurs or frozen embryos are
transferred, the preferred outcome is cumulative live birth per
woman over the period of observation. Secondary pregnancy
outcomes that merit reporting are serum pregnancy, ongoing
pregnancy (R12 weeks), multiple pregnancy, and accounting
for all pregnancy losses. Both male and female outcomes,
other than live birth, could be the primary outcome and
should be justiﬁed. When live birth is not the primary
endpoint and infertility treatment is given (e.g., embryos are
transferred), live birth should still be reported.
Example: Reporting live birth (deﬁned as a delivery after
R20 weeks' gestation) as primary outcome is preferred
(including gestational age, birthweight, and sex of in-
fant). ‘‘The primary outcome was the cumulative rate of preg-
nancy resulting in at least one live birth. Secondary outcomes
were the rates of pregnancy, implantation, multiple births (as
a percentage of live births), spontaneous abortion, and ectopic
pregnancy. A pregnancy was deﬁned as a positive test for hu-
man chorionic gonadotropin in urine (>20 IU per liter) or a
serum level of human chorionic gonadotropin 2 IU per liter
or more 2 weeks after embryo transfer’’ (93).
Explanation. Authors should report the outcome that couples
most want—a live birth—and avoid surrogate outcomes such
as ovulation, gamete number or quality, or embryo fertiliza-
tion or implantation rates (43, 56). It is difﬁcult to mandate
that the primary outcome for an infertility trial should
always be a live birth, because there are multiple conditions
or actions after the establishment of a pregnancy that may
bias the outcome of live birth. For example, older and more
obese women are more likely to miscarry (12, 78); and
develop gestational disorders such as diabetes and
hypertension (6, 98). If the trial aimed to reduce the
iatrogenic epidemic of multiple pregnancy (51), then a
primary outcome of live birth may miss the true incidence
of iatrogenic multiple pregnancy. Multiple pregnancies are
more likely to self-reduce, i.e., individual implantationsVOL. 102 NO. 4 / OCTOBER 2014
Fertility and Sterility®miscarry, normalizing the multiplicity (58). Patients with
multiple pregnancy may also choose selective reduction, in
which individual gestational sites are selectively aborted
(23). These conditions of vanishing twins (81), later intrauter-
ine fetal deaths (79) and selective reductions of multiple preg-
nancy (26, 69) may be associated with increased perinatal
morbidity and mortality for the surviving fetus(es) and
mother.
The decision to advocate for live birth to be reported, even
when not the primary outcome, is made despite the concerns
about the hurdles in obtaining this information, the admittedly
strong correlation between ongoing pregnancies and live
births, and delays in publishing while awaiting live birth
causes (16). We acknowledge that ongoing pregnancy is a
good surrogateoutcomeof live birth.However, every surrogate
outcome has inherent ﬂaws, and even the most sacrosanct of
surrogate outcomes (e.g., serum cholesterol levels for cardio-
vascular events or glycemic control for mortality in diabetes)
have been negated by prospective randomized trials. For
example, torcetrarib, a potent cholesteryl ester transfer protein
inhibitor, which lowers cholesterol more than comparable
statin therapy (73), was found to have an increased rate of
morbidity and mortality (3). More intensive glycemic control
in type 2 diabetes has been theorized to improve morbidity
andmortality in patientswith type 2 diabetes. However, a clin-
ical trial that achieved near-normal glucose control with mul-
tiagent therapy was associated with signiﬁcantly increased
risks of death from any cause and death from cardiovascular
causes (29), the very outcomes the trial (and intensive treat-
ment) were thought to prevent (24).
It is very possible that an intervention may have a differ-
ential effect on pregnancy loss, which may be missed if
pregnancies are not tracked to completion. The Pregnancy in
Polycystic Ovary Syndrome I trial noted a higher ﬁrst-
trimester miscarriage rate with metformin (40%) than with
clomiphene citrate (22%), which, though not signiﬁcant
(P¼ .1) (53), may be a vital component of a future meta-
analysis that may provide further insight into this issue (74).
There are varying deﬁnitions of pregnancy status (i.e., concep-
tion, implantation, clinical, ongoing pregnancy) as well as
varying deﬁnitions of pregnancy loss, such as biochemical
pregnancy, missed abortion, miscarriage, etc. We recommend
using standardized ICMART deﬁnitions of these (103), or if
necessary to alter them, clearly deﬁning the deﬁnitions used
to deﬁne secondary pregnancy outcomes.
There may also be variable effects of treatments on harms
of therapy that may be missed if live birth outcomes are not
tracked. For example, live birth rates may be higher after a
fresh embryo transfer compared with a frozen embryo trans-
fer (60), but the perinatal outcomes for children appear to be
worse when the conception is due to a fresh transfer versus a
frozen thawed embryo transfer (48, 50, 63). It is also likely
that any differential effect on fetal anomalies would be
completely missed if ongoing pregnancy was the primary
outcome of infertility trials, because there is extremely
limited sensitivity of ﬁrst-trimester obstetrical ultrasound to
detect them (9, 28).
Most national and international oversight committees of
assisted reproduction technology (ART) require reporting ofVOL. 102 NO. 4 / OCTOBER 2014live birth after IVF. However, there is also debate about the
deﬁnition of a live birth, and this is confounded by multiple
pregnancy, where there may be divergent outcomes (i.e., con-
current stillbirth and live birth of a twin pregnancy). The
Society for Assisted Reproductive Technology in the United
States deﬁnes live birth as delivery of one or more live-born
infants (with no cutoff for gestational age) with delivery of
multiple infants deﬁned as one live birth delivery. A multiple
birth is deﬁned as a birth of two or more infants, at least one
of whom was a live birth. The Centers for Disease Control's
National Center for Health Statistics, which uses live birth
records rather than delivery records, considers a live-born
infant with one or more stillborns to be a singleton birth
(64), thus underestimating multiple pregnancies.
There is no consensus on the minimum duration of gesta-
tion to qualify as a live birth. ICMART deﬁnes a delivery as
‘‘the expulsion or extraction of one or more fetuses from the
mother after 20 completed weeks of gestational age,’’ but a
live birth as any expulsion of a fetus showing signs of life,
‘‘regardless of the duration of the pregnancy’’ (103). Thus, a
fetus born at 18 weeks with a heartbeat and attempted respi-
ration can display signs of life with no chance for survival.
Twenty weeks of gestation both conventionally and by
deﬁnition (103) is the dividing point between a nonviable preg-
nancy (termed conventionally a miscarriage or spontaneous
abortion) and a viable pregnancy that can result in a live birth.
Despite the remarkable progress of neonatology in treating
early preterm infants, the window of viability remains some-
where between 23 and 24 weeks' gestation. We acknowledge
that the early preterm births have markedly greater chances
of morbidity and mortality with live births after 20–22 weeks
having virtually no chance of survival. However, to provide
uniform reporting, be consistent with conventional practice,
and allow a comparison with public birth records worldwide,
we recommend using the WHO deﬁnition of live birth as any
infant born alive with a gestational ageR20 weeks (101).
There was a vigorous discussion in the conference advo-
cating a more stringent choice of a healthy live born as the
optimal outcome for an infertility trial. However, given the dif-
ﬁculty in arriving at a cutoff point of 20 weeks to deﬁne live
birth, we did not see the possibility of achieving any consensus
about the deﬁnition of a healthy baby. There have been at-
tempts to deﬁne a healthy birth, for example, ‘‘singleton live
births at term with birthweight more than 2,500 g,’’ that have
been used to better identify optimal outcomes in ART (45). A
healthy infant cannot always be clearly ascertained at birth
and requires further observation and testing throughout the
neonatal and infancyperiod (88). To extend the periodofobser-
vation beyond delivery would further burden researchers and
participants, although both the optimal outcome and period
of infant observation is one that we will surely revisit in future
conferences. Therewas strong support for continued follow-up
of infants born from infertility treatment.
We recommend, however, reporting birthweight, given
the now well established association of decreased birthweight
in singleton pregnancies after ART (22) as well as the tendency
of multiple pregnancy to lead to lower birthweights even
when corrected for premature delivery. This is currently rarely
reported in clinical trials (54). We address the issue of tracking959.e5
SUPPLEMENTAL MATERIALand reporting preterm delivery below, under ‘‘Reporting
adverse events during treatment and during and after preg-
nancy.’’ We recommend reporting the sex of the infant
because of the greater birthweight of boys compared to girls,
as well as the lower mortality rate for female infants (91).
Additionally, certain treatments may either unintentionally
or intentionally select for speciﬁc sex of the offspring. Prena-
tal genetic screening (PGS) of embryos is an example of a ther-
apy that could be used for sex selection. Also, a treatment that
results in a longer time to pregnancy (89) or alters the baseline
hormonal milieu of the ovary (39, 40) may alter the sex ratio.
Example: reporting cumulative live birth. ‘‘Patients under-
went a maximum of six treatment cycles of IUI in a sponta-
neous cycle, IUI in a mildly hyperstimulated cycle, or IVF
.. The primary end point of the study was pregnancy result-
ing in at least one live birth after treatment. Since our measure
of the efﬁcacy of a treatment programme was whether a
couple succeeded in conceiving under infertility treatment,
the delivery of more than one babywas given the same weight
as the delivery of a singleton. Pregnancy rates included only
the pregnancies that resulted in at least one live birth. Preg-
nancy rates were calculated per started cycle and cumula-
tively after termination of the treatment programme’’ (30).
Explanation. Cumulative live birth is the live birth per
woman over a deﬁned time period (or number of treatment
cycles). There are many reasons to report cumulative live birth
when multiple cycles are used. Often, multiple cycles are
required to achieve the maximum treatment effect (no one re-
ports remission or cure rates after one cycle of radiation or
chemotherapy for cancer). Physicians prescribe a varying
number of cycles of treatment. Patients make choices based
on cumulative live birth rates. Studies withmultiple treatment
cycles may show clear evidence of either declining returns
with continued therapy or a time-related beneﬁt. For
example, prolonged treatment with metformin for ovulation
induction has been associated with better results in multiple
trials of women with PCOS (53, 72, 75).
Furthermore, it is possible with IVF that one cycle of
stimulated IVF can result in multiple chances for pregnancy.
With the change in practice to transferring single embryos
or proceeding with elective cryopreservation, there are
now more embryos for future transfer. The most useful
outcome to guide clinical practice for infertility treatments
is the cumulative live birth rate from one initiated (stimu-
lated) cycle, because this considers the overall outcome of
one active treatment cycle and includes all the available
embryos until either a live birth occurs or no embryos
remain (44). Focusing solely on the outcome of a fresh
transfer as a trial outcome biases the treatment choice by
encouraging multiple-embryo transfer to elevate live birth
rates (68). Using these cumulative outcomes provides more
information to the couple/woman and her fertility specialist
about the likelihood of having a baby after one cycle of IVF
treatment using all available embryos. An alternative
outcome that also takes more than one embryo transfer
into account is the cumulative live birth rate at the end of
some prespeciﬁed time period, for example up to 1 year af-
ter an initiated cycle (35).959.e6Example: secondary outcomes that merit reporting. ‘‘Se-
condary outcomes included biochemical pregnancy, clinical
pregnancy, miscarriage, and live birth. Biochemical preg-
nancy was deﬁned as a serum b human chorionic gonado-
tropin level of at least 2 IU per liter 2 weeks after embryo
transfer. Clinical pregnancy was deﬁned as the presence of
a gestational sac conﬁrmed by transvaginal ultrasound ex-
amination at a gestational age of 7 weeks’’ (65).
Explanation. Accounting for pregnancy loss and the timing
of pregnancy loss is important to identify treatment-related
effects and potential harms. The follow-up of pregnancies
from a positive pregnancy test until delivery or pregnancy
loss also provides patients with information about the likeli-
hood of pregnancy loss. Approximately 30% of pregnancies
are lost after a positive pregnancy test and 5% of pregnancies
have been shown to be lost between the ultrasound conﬁrma-
tion of a clinical pregnancy and delivery (16).
However, commonly reported terms of pregnancy and
pregnancy loss have no uniform deﬁnitions. For example, is
a biochemical pregnancy (i.e., positive urine or serum preg-
nancy test) the earliest form of detectable pregnancy (i.e., a
positive outcome) or a potential early form of miscarriage
(i.e., a negative outcome)? Many studies of infertility end
with a positive pregnancy test as the outcome. Clinical preg-
nancy is often deﬁned as the ultrasound visualization of an
intrauterine gestational sac, but does not always imply fetal
cardiac activity. Obviously a gestational sac visualized on ul-
trasound 6 weeks after an embryo transfer with a fetal pole
but no fetal cardiac activity would not be considered a desired
outcome by the couple or the clinician. Furthermore, an
ongoing pregnancy, which is often used to imply an intra-
uterine gestational sac with a fetal pole with cardiac activity,
is variably deﬁned at 6, 8, 10, or 12 weeks or unspeciﬁed. We
recommend that all deﬁnitions of pregnancy and pregnancy
loss be clearly deﬁned in the reporting of secondary outcomes
and include a table (Table 2) with suggested consensus deﬁni-
tions building on the established ICMART deﬁnitions (103).
Multiple pregnancies (including degree, i.e., twins, trip-
lets, quadruplets, etc.) should always be reported in any infer-
tility trial where ovulation induction or stimulation occurs
and where multiple embryos are transferred. Ongoing and
clinical pregnancies are secondary outcomes that could be re-
ported if it is not possible to report live birth, but it is not ideal
owing to pregnancy loss from still birth or preterm delivery.
This is particularly important if multiple pregnancy rates
are high within the population of infants.
Example: fertility potential, a varicocele trial in adolescent
males reporting parameters of gamete function rather than
pregnancy. ‘‘Before treatment, the mean left testis volume in
groups 1 (n ¼ 26) and 2 (n ¼ 27) (20.0 mL, 95% conﬁdence
interval [CI] 18.2 to 21.8; and 21.6 mL, 95% CI 19.4 to 23.8;
respectively) were signiﬁcantly smaller than those in the con-
trol group (n ¼ 19) (24.5 mL, 95% CI 22.7 to 26.4). During
follow-up, left testis volumes of the treated group were similar
to those in the control group (24.2 mL; 95% CI 22.2 to 26.1;
and 24.8 mL, 95% CI 23.0 to 26.7; respectively) and signiﬁ-
cantly (P< .001) different from the untreated group
(20.3 mL, 95% CI 18.8 to 21.8). A signiﬁcant increase in leftVOL. 102 NO. 4 / OCTOBER 2014
TABLE 2
Consenus deﬁnitions of pregnancy and live birth for reporting outcomes of clinical trials with reference to the International Committee for
Monitoring Assisted Reproductive Technology (ICMART)–World Health Organization (WHO) deﬁnitions (103).
Pregnancy ICMART deﬁnition Harbin Consensus deﬁnition
Biochemical pregnancy A pregnancy diagnosed only by the detection of hCG
in serum or urine and that does not develop into a
clinical pregnancy
Agree
Clinical pregnancy A pregnancy diagnosed by ultrasonographic
visualization of one or more gestational sacs or
deﬁnitive clinical signs of pregnancy. It includes
ectopic pregnancy. Note: Multiple gestational sacs
are counted as one clinical pregnancy.
Agree, except with including ectopic pregnancy in
clinical pregnancy rate. Count ectopic pregnancy
as an adverse event.
Clinical pregnancy
with heart rate
A pregnancy diagnosed by ultrasonographic or clinical
documentation of at least one fetus with heart
beat. It includes ectopic pregnancy.
Agree, except with including ectopic pregnancy in
clinical pregnancy rate. Count ectopic pregnancy
as adverse event.
Ongoing pregnancy No ICMART deﬁnition Visualization of an intrauterine gestational sac with
fetal pole and fetal cardiac activity at predeﬁned
gestational age or gestational age range
(usually 8–12 weeks).
Live birth The complete expulsion or extraction from its mother
of a product of fertilization, regardless of the
duration of the pregnancy, which, after such
separation, breathes or shows any other evidence
of life, such as heart beat, umbilical cord pulsation,
or deﬁnite movement of voluntary muscles,
regardless of whether the umbilical cord has been
cut or the placenta is attached.
Agree, but gestational age must beR20 weeks
Note: In any case, deﬁnitions should be clearly deﬁned and multiple pregnancies identiﬁed at all stages of ultrasound monitoring of pregnancy.
Harbin Consensus Conference Workshop Group. New reporting statement for infertility trials. Fertil Steril 2014.
Fertility and Sterility®(P< .01) as well as right (P< .05) testis volume was observed
after treatment. Semen parameters before treatment were
not signiﬁcantly different among the three groups. Sperm
concentration increased signiﬁcantly (P< .01) from 47.4 
106/mL (95% CI 42.5 to 53.3) to 68.9  106/mL (95% CI
50.6 to 87.2) in the treated group, whereas semen quality in
the untreated and control groups did not change’’ (52).
Explanation. Some studiesmay be designedwith intermediate
or surrogate primary outcomes. For example, as noted above in
studies of adolescents or of fertility preservation, it is very un-
likely that pregnancy or live birth is a realistic possibility to
track. Instead, some parameter of gamete function, such as
noted above, testis size or semen analysis parameters, are
suitable outcomes (52). In studies of adult men with mild to
moderate male-factor infertility, treatments with a range of
medications, including antioxidants (86) or surgery in the
case of varicoceles (62), may improve sperm parameters,
such as semen volume, concentration, and motility, and are
an important outcome to report.Weacknowledge thatweplace
little faith in surrogate outcomes, and that there is substantial
overlap in semen parameters between fertile and infertile men,
making any cutoffs dubious (32). However, any pregnancies
that result should be reported and tracked to live birth.Section/Topic: Results
Item no. 13a: participant. Modiﬁed checklist item: Number
of couples who were screened and eligible.
Example: ﬂow chart of a study. (Fig. 1).
Explanation. The trial should identify the number of couples
who were screened and those who met eligibility. Ideally,VOL. 102 NO. 4 / OCTOBER 2014screening failures should be identiﬁed on the basis of the
failed inclusion or met exclusion items. This helps clarify
the external validity of such treatments in the larger infertility
population.
Item no. 15: baseline data. Modiﬁed checklist item: State
the duration of infertility (including whether it is primary or
secondary), relevant obstetrical history, and cause of infer-
tility in women and men if possible.
Example: table from a trial of unexplained infer-
tility. (Table 3).
Explanation. It is important to know the duration of infertility,
because this has consistently been shown to be negatively
correlated with chance of pregnancy, even independently
from maternal age (36, 84, 95). Furthermore, any previous
pregnancy increases the chance for a subsequent pregnancy,
so generally patients with secondary infertility do better than
patients with primary infertility (36, 84, 95). Because
infertility is multifocal, couples may have more than one
infertility risk factor. Also, various infertility diagnoses have
varying prognoses for live birth. For example, before the
advent of ICSI, severe oligospermia had a poor prognosis for
pregnancy, even with IVF. Additionally, endometriosis,
especially severe endometriosis, may have a markedly
diminished chance for live birth after IVF compared with
other factors, such as tubal factor (2). It is important to
delineate the causes of infertility identiﬁed in the history or
screening in the report of the trial. Depending on the focus of
the trial, obstetrical history may also be relevant. For
example, in a randomized controlled trial of recurrent
pregnancy loss, the number of consecutive pregnancy losses
was inversely proportional to the chance for live birth (83).959.e7
FIGURE 1
Flow chart from a randomized trial of intrauterine insemination (IUI)
or in vitro fertilization (IVF) in idiopathic subfertility and male
subfertility (30).
Harbin Consensus Conference Workshop Group. New reporting statement for infertility tri-
als. Fertil Steril 2014.
SUPPLEMENTAL MATERIALFurther, there may be different mechanisms involved for those
with high-order pregnancy loss.
Item no. 16: numbers analyzed. Modiﬁed checklist item:
The preferred unit of analysis is per randomized individual/
couple (not cycles or oocytes/embryos) for a speciﬁed period
of time (preferably displayed with life table analysis). Use of
per-cycle analysis should be justiﬁed and, if used, must
account for individuals receiving multiple cycles.
Example: life table analysis of singleton live birth rates of
mild versus standard ovarian stimulation for IVF. (Fig. 2).
Explanation. We have recommended that the unit of analysis
be the woman, because randomization of gametes, embryos,TABLE 3
Baseline characteristics at randomization according to allocation to expe
insemination for unexplained infertility.
Expectant management (n[
Age (y), mean (SD)
Women 32 (3.4)
Men 34 (5.1)
Duration of infertility (mo), median (IQR) 30 (25–38)
Primary infertility 135 (70)
Mild endometriosis 17 (9)
Surgical treatment for endometriosisa 3 (18)
Mild male-factor infertility 9 (5)
BMI (women, kg/m2), median (IQR) 23 (21–25)
Sperm variables
Density (million/mL), median (IQR) 62 (39–95)
Motility (%), mean (SD) 52 (15.6)
HADS subscaleR11
Anxiety 29 (15)
Depression 3 (2)
Note: Values are presented as n (%) unless stated otherwise. Adapted from (8). HADS ¼ Hospital A
a Percentage of those who had mild endometriosis.
Harbin Consensus Conference Workshop Group. New reporting statement for infertility trials. Fertil S
959.e8or cycles can result in unit of analysis error (94). Eggs from
the same woman, or sperm from the same man, are interre-
lated and when combined with those from other women chal-
lenge the premise of independence necessary for statistical
analysis. Additionally, multiple observations from the same
individuals can lead to an unpredictable treatment bias in
the estimate of treatment effect. It will also inﬂate the power
of the sample size and imbue it with greater precision than
merited. Such reports will have a spurious narrowing of the
conﬁdence intervals with corresponding lower P values that
can lead to a type I statistical error. Many infertility trials
have been weakened by ‘‘unit of analysis’’ errors (94).
Life table analysis is recommended because it displays
graphically the chances over time of pregnancy or live birth
from the point of randomization. This allows visual demon-
stration of absolute differences in pregnancy (or preferably
live birth) rates and how they change over time. It will answer
the clinically relevant questions not only of relative efﬁcacy
but the important time-to-pregnancy issue. Time to preg-
nancy may not be applicable when the study compares the
effectiveness of a single cycle of infertility therapy, but single
cycles are rarely recommended as exclusive therapies. When a
period of time is chosen as the period of treatment, it is recom-
mended that the number of treatment cycles be reported be-
tween groups.
Item no. 16: numbers analyzed. Modiﬁed checklist item:
Clearly describe what happens to all multiple pregnancies,
including fetal reduction and vanishing gestations. Report
multiple pregnancy outcome both per woman and per
pregnancy. Separate out twin/triplets/quads/higher-order
multiple pregnancies.
Example: reporting multiple pregnancies. ‘‘A total of 351
patients were randomly assigned to undergo transfer of either
a single cleavage-stage embryo (176 patients) or a single
blastocyst-stage embryo (175 patients) .. The overall rate
of multiple births was 2.1% (2 of 94 deliveries). Both multiplectant management, clomiphene citrate, or unstimulated intrauterine
193) Clomifene citrate (n[ 194) Insemination (n[ 193)
32 (3.5) 32 (3.7)
34 (5.1) 34 (5.2)
30 (24–38) 30 (25–40)
144 (74) 134 (69)
9 (5) 13 (7)
2 (22) 1 (8)
11 (6) 14 (7)
23 (22–26) 23 (21–26)
65 (38–105) 58 (35–98)
53 (16.4) 53 (15.6)
28 (14) 23 (12)
1 (1) 2 (1)
nxiety and Depression Scale; IQR ¼ interquartile range.
teril 2014.
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FIGURE 2
Proportions of pregnancies leading to cumulative term live birth
within 12 months after starting IVF. Mild: mild ovarian stimulation
with GnRH antagonist and single-embryo transfer. Standard:
standard ovarian stimulation with GnRH antagonist and dual-
embryo transfer. The shaded area represents the singleton live birth
rate after 12 months. Adapted from (35).
Harbin Consensus Conference Workshop Group. New reporting statement for infertility tri-
als. Fertil Steril 2014.
Fertility and Sterility®pregnancies occurred in the cleavage-stage group and con-
sisted of monozygotic twins’’ (76).
Explanation. Multiple pregnancy is a common iatrogenic risk
of infertility therapy. In the United States it has been esti-
mated that in 2011, a total of 36% of twin births and 77%
of triplet and higher-order births resulted from conception as-
sisted by fertility treatments, with decreased rates over time of
triplet and high-order but increasing twin pregnancy rates
(51). Multiple pregnancies have higher rates of pregnancy
loss (58) and can experience a loss of a fetus and still progress
to term, though pregnancies with vanishing twins are likely
higher risk than singleton gestations (81). Multiple pregnan-
cies are at increased risk for preterm delivery through preterm
labor or iatrogenic delivery for maternal or fetal complica-
tions. Furthermore, even infants from uncomplicatedmultiple
pregnancies that go to term tend to be smaller for gestational
age than those from a singleton pregnancy. Thus it is impor-
tant to report the fate of multiple pregnancies and their
contribution to adverse events.Item no. 19: harms
Modiﬁed checklist item: Preferred items to report include
ovarian hyperstimulation syndrome (OHSS), infection,
bleeding, multiple pregnancy (see also item no. 16) and
maternal pregnancy complications, and harms or unintended
effects on the fetus/newborn, including congenital
abnormalities, and major neonatal complications as well as
infant developmental delays or medical problems.VOL. 102 NO. 4 / OCTOBER 2014Example: reporting adverse events during treatment and
during and after pregnancy. A table, which may be the
best way to capture the adverse events (Table 4).
Explanation. Trials involving infertility should report all of
the potential harms involving both the men and the women
in the trial as well as any adverse effects occurring during
pregnancy and parturition and to the fetus and neonate. Risks
of any infertility treatment include risks inherent to the infer-
tility itself, including the possible causes of the infertility
(such as PCOS, oligospermia, and advanced maternal age
should any pregnancy result); risks inherent to pregnancy,
delivery, and childhood; and risks inherent to the infertility
treatment itself. Thus, it is important to include all harms dur-
ing the trial so that any excess harms associated with the
infertility treatment can be teased out from other harms.
From this consideration of possible risks, it is clear that any
treatment probably includes some small increased risk above
that occurring in spontaneously conceived pregnancies. Thus,
it is important to report all harms in an infertility trial, and
these harms must include both the male and the female and
the resulting pregnancy and neonate.
As an example, it is worth considering the risks that have
been identiﬁed as occurring during IVF. It has been well docu-
mented that multiple pregnancy is the risk of IVF associated
with the greatest maternal and neonatal risks (51). Meta-
analyses have also documented that even resulting IVF single-
tons are associated with signiﬁcantly higher odds of perinatal
mortality (odds ratio [OR] 2.2), preterm delivery (OR 2.0), low
birthweight (OR 1.8), very low birthweight (OR 2.7), and small
for gestational age (OR 1.6) (38). There have also been sugges-
tions that birth defects may be increased in children born as a
result of IVF (21). There have also been questions as towhether
the risk of cancer in children and young adults conceived as a
result of IVF are increased (46, 100).
However, all of these risks must be considered in context.
Outcomes in subfertile women conceiving spontaneously
within 5 years of registering at an IVF clinicwere also increased
compared with those in matched fertile control subjects (41).
After adjustment, the subfertile women had increased odds of
hypertension or preeclampsia (OR 1.29), antepartum hemor-
rhage (OR 1.41), perinatal death (OR 2.19), low birthweight
(1.44), preterm birth <37 weeks (OR 1.32), preterm birth
<31 weeks (OR 2.37), and cesarean delivery (OR 1.56). More-
over, there was also weak evidence for increased birth defects
(OR 1.30) and gestational diabetes (OR 1.25).Without informa-
tion about infertile women conceiving without any treatment,
clinicians and patients might well conclude that IVF had more
risks than it apparently does. Collecting these adverse events
prospectively in controlled clinical trials allows for clearer
treatment-related morbidity rather than association with the
underlying diagnosis.
Similarly there are suggestions that culture conditions can
affect risks in IVF. Data from the Swedish birth registry indicate
that infants born after blastocyst-stage transfers are at a higher
risk for both preterm birth (OR 1.35) and congenital malforma-
tions (OR 1.40) compared with infants born after cleavage-
stage transfers (47). There are even suggestions that themedium
used in the culture of the embryos can affect success and959.e9
TABLE 4
Table of adverse events from the Pregnancy in Polycystic Ovary Syndrome I study, a randomized controlled trial of clomiphene, metformin, or
combination of both for up to six cycles to treat infertility in women with polycystic ovary syndrome (from Legro et al., 2007).
Event Clomiphene group Metformin group Combination therapy group
Before conception in subjects who received a study drug
Total no. of subjects 209 208 209
Serious adverse event
Hemorrhagic corpus luteum cystb 1 (0.5) 0 0
Hypersensitivity reactionc 0 1 (0.5) 0
Bronchitis or back paind 1 (0.5) 0 1 (0.5)
Deathe 0 1 (0.5) 0
Other adverse event
Abdominal distentionf 45 (21.5) 56 (26.9) 39 (18.7)
Abdominal pain or discomfortg 110 (52.6) 123 (59.1) 137 (65.6)
Constipation 32 (15.3) 21 (10.1) 22 (10.5)
Diarrheag,h 48 (23.0) 135 (64.9) 126 (60.3)
Dyspepsiah 9 (4.3) 24 (11.5) 14 (6.7)
Flatulence 38 (18.2) 37 (17.8) 39 (18.7)
Nauseag,h 82 (39.2) 128 (61.5) 138 (66.0)
Stomach discomfort 8 (3.8) 15 (7.2) 16 (7.7)
Vomitingg,h 28 (13.4) 62 (29.8) 72 (34.4)
Decreased appetiteg 17 (8.1) 27 (13.0) 33 (15.8)
Back pain 25 (12.0) 22 (10.6) 22 (10.5)
Dizziness 26 (12.4) 35 (16.8) 34 (16.3)
Impaired sense of taste 10 (4.8) 11 (5.3) 10 (4.8)
Headache 92 (44.0) 88 (42.3) 87 (41.6)
Altered mood or mood swings 32 (15.3) 36 (17.3) 27 (12.9)
Hot ﬂashesf,h 58 (27.8) 32 (15.4) 59 (28.2)
Adnexal painf 10 (4.8) 4 (1.9) 12 (5.7)
Anovulatory bleedingf,h 6 (2.9) 18 (8.7) 7 (3.3)
Breast tenderness or pain 41 (19.6) 36 (17.3) 47 (22.5)
Dysmenorrhea or crampsf,h 42 (20.1) 26 (12.5) 43 (20.6)
Sore throat 13 (6.2) 14 (6.7) 8 (3.8)
Respiratory tract infection 27 (12.9) 24 (11.5) 16 (7.7)
Fatigue 38 (18.2) 42 (20.2) 45 (21.5)
After conception (with observed fetal heart motion) in subjects who discontinued study drug
Total no. of subjects 50 18 65
Serious adverse event before birth
Pregnancy loss after 12 weeks 2 (4.0) 0 4 (6.2)
Ectopic pregnancy 2 (4.0) 0 2 (3.1)
Cervical incompetence or preterm labori 1 (2.0) 0 1 (1.5)
Severe preeclampsia 0 0 2 (3.1)
Congenital anomalyj 0 0 2 (3.1)
Other adverse event before birth
Preterm labor 4 (8.0) 1 (5.6) 5 (7.7)
Mild preeclampsia 6 (12.0) 1 (5.6) 7 (10.8)
HELLP syndrome 1 (2.0) 0 1 (1.5)
Gestational diabetes
Diet controlled (class A1) 6 (12.0) 1 (5.6) 4 (6.2)
Insulin required (class A2) 3 (6.0) 1 (5.6) 1 (1.5)
Intrauterine growth restriction 0 0 0
Preterm premature rupture of membranesk 1 (2.0) 1 (5.6) 3 (4.6)
Placental abruption 2 (4.0) 0 2 (3.1)
Placenta accrete 0 0 0
Placenta previa 1 (2.0) 0 1 (1.5)
Other placental abnormality 1 (2.0) 1 (5.6) 1 (1.5)
Other pregnancy complication 6 (12.0) 2 (11.1) 4 (6.2)
Serious adverse event after birth 0 0 0
Other adverse event after birth
Postpartum depression requiring intervention 1 (2.0) 0 2 (3.1)
Endometritis 0 0 3 (4.6)
Postpartum hemorrhage 2 (4.0) 0 0
Other disorder 3 (6.0) 1 (5.6) 3 (4.6)
Note: HELLP syndrome denotes hemolysis, elevated liver enzyme levels, and a low platelet count.
aDiagnoses after pregnancy were made by the treating physician.
b This event resulted in hospitalization and surgery.
c One subject in the metformin group had an anaphylactic reaction during a dinner of shellﬁsh and tuna, resulting in a visit to the emergency department, during which patient was treated with
Benadryl and a corticosteroid and discharged home. She took a dose of metformin that evening and continued in the study.
d The subjects with bronchitis (in the clomiphene group) and back pain (in the combination-therapy group) were hospitalized.
e One patient in the metformin group had a fatal subarachnoid hemorrhage. She had received the drug for one cycle and was not pregnant, according to the autopsy report.
f P< .05 for the comparison between combination therapy and metformin.
g P< .05 for the comparison between combination therapy and clomiphene.
h P< .05 for the comparison between clomiphene and metformin.
i One subject in the clomiphene group had cervical incompetence and delivered at 37 weeks, and one subject in the combination-therapy group had preterm labor.
j One subject, who had severe preeclampsia and nephrolithiasis during her pregnancy, delivered an infant with the Prader–Willi syndrome, and one patient delivered an infant with a congenital
diaphragmatic hernia.
k Preterm premature rupture of membranes is membrane rupture before contractions begin and at less than 37 weeks' gestation.
Harbin Consensus Conference Workshop Group. New reporting statement for infertility trials. Fertil Steril 2014.
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Fertility and Sterility®birthweight (25) and that the air quality in the vicinity of the
laboratory may even affect conception rates of IVF (57). This
example stresses the importance of reporting all of the details
associated with any trial involving treatment for infertility.
Preferred items to report in any trial involving treatment for
infertility include the risks of OHSS as a result of ovulation in-
duction or stimulation, pelvic and other infections, uterine
bleeding, multiple pregnancy, and maternal complications of
pregnancy. Any harmful effects on the fetus and newborn
should be reported as well, including congenital abnormalities
and major neonatal complications and subsequent develop-
mental problems and delays. Placed in context, it is clear that
the ﬁnal risks associated with IVF will not be apparent until
years from now when it will be possible to evaluate the lifetime
risks of IVF in the resulting children. Although it will not be
possible to evaluate all of the risks associatedwithany infertility
trial when the data are ﬁrst published, there should be every
effort to report as many as possible. Trials of infertility should
not be reportedwithout collecting data on resulting pregnancies
and birth outcomes. We include a summary table of maternal
and fetal outcomes to report in infertility trials (Table 5).SECTION/TOPIC: DISCUSSION
Item no. 22: interpretation
Modiﬁed checklist item: Balance outcomes and any
competing interests of female and male participants and
infant.
Example: balance competing interests of participant and
infant. ‘‘We conclude that for infertile couples in which the
woman has no identiﬁable infertility factor and the manTABLE 5
Potential harms to participants in an infertility trial that merit reporting.
Time Womena
Delivery of the
infertility
intervention
Burden of treatment/stress,c OHSS,b
bleeding, infection, adverse oocyte
qualityc
Burden
adv
Pregnancy Multiple pregnancy, ectopic pregnancy,
pregnancy loss (all trimesters),
pregnancy-related hypertension,d
gestational diabetes,e abnormal
placentation,f gestational trophoblastic
diseaseg
Delivery Cesarean section/operative deliveries
Postpartum and
neonatal/infancy
Thromboembolism, postpartum depression,
lactation rates
a A death of participating male or female as well as resulting fetus/infant should be reported.
b OHSS (ovarian hyperstimulation syndrome) is an exaggerated and symptomatic response to ovula
c There are currently no accepted standards for determining these parameters.
d Pregnancy-related hypertension includes preeclampsia deﬁned as new-onset hypertension with p
women with preeclampsia, and HELLP syndrome (hemolysis, elevated liver enzymes, low platelets)
e Gestational Diabetes has varying deﬁnitions depending on country of origin. The USA uses a two-
glucose test (96), whereas most of the rest of the world uses a 2-hour 75-g oral glucose test (37).
f Abnormal placentation includes placenta previa, placental abruption, placenta accreta, increta, an
g Gestational trophoblastic disease includes hydatidiform mole (complete or partial), persistent/in
tumors.
h FGR is most commonly deﬁned as an ultrasound-determined estimated fetal weight below the 3r
i SGA is most commonly deﬁned as aweight below the 10th percentile for the gestational age. At term
gestational age. At term this isR4,000 g (4).
j PTD is deﬁned by a delivery before 37 weeks' gestation (92).
Harbin Consensus Conference Workshop Group. New reporting statement for infertility trials. Fertil S
VOL. 102 NO. 4 / OCTOBER 2014has motile sperm, the combination of superovulation and in-
trauterine insemination is an effective means of achieving
pregnancy. Moreover, the effects of superovulation and intra-
uterine insemination on pregnancy appear to be independent
and additive. In recommending treatment options to couples,
physicians should weigh these results against those for
in vitro fertilization; they should also consider the costs of
the various procedures, the results of semen analyses, the
woman's age, and the incidence of ovarian hyperstimulation
and high-order multiple pregnancies’’ (31).
Explanation. There are multiple factors that can create
competing interests between the fetus and mother that have
been well documented in the obstetrics literature (15, 33).
Many of these are also relevant to infertility trials. For
example, women may become pregnant with multiple
obstetrical risk factors for poor pregnancy outcomes. Such
conditions as obesity, PCOS, or both are associated with
increased risks of adverse pregnancy outcomes, including
pregnancy-induced hypertension, preterm labor, and gesta-
tional diabetes (10, 13, 17). These pregnancies pose risks to
both mother and infant, where iatrogenic delivery is often
indicated to prevent progression of the disease in the mother
(e.g., preeclampsia to eclampsia) at the cost of infant
prematurity.
There are also competing risks unique to infertility trials.
Perhaps the most common is iatrogenic multiple pregnancy,
which increases the risk of the mother for almost all major
pregnancy complicationswhile predisposing the infants topre-
term delivery. Selective reduction has commonly been used to
prevent maternal and fetal complications in high-order multi-
ple pregnancy (97). Other competing interests may appearMena Fetus/Infanta
of treatment/stress,c
erse semen qualityc
Adverse embryo quality,c fetal anomaly,
fetal growth restriction (FGR)h
Small or large for gestational age (SGA/LGA),i
preterm delivery (PTD),j anomalies detected
by obstetrical screening
Anomalies detected after birth, neonatal
intensive care unit admission, length of stay
tion induction therapy (82).
roteinuria after 20 weeks' gestation, eclampsia deﬁned as the development of seizures in a
(1).
step screening approach with a 1-hour 50-g oral glucose test followed by a 3-hour 100-g oral
d percreta.
vasive gestational trophoblastic neoplasia, choriocarcinoma, and placental site trophoblastic
d percentile for gestational age (67).
this is%2,500 g. LGA ismost commonly deﬁned as aweight above the 10th percentile for the
teril 2014.
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SUPPLEMENTAL MATERIALearlier after infertility treatment. For example, OHSS can have
early forms, related to the triggering of ovulation most
commonly from exogenous hCG hormone, and late forms
due to endogenous hCG from implanting pregnancy(ies) (66,
77). Both forms can be life threatening, though the early one
may be circumscribed owing to the limited administration of
exogenous hCG, whereas the late form can progressively
worsen due to increasing endogenous hCG levels from the
pregnancy(ies). Elective pregnancy termination has been
performed in rare cases of severe OHSS (19).
CONCLUDING REMARKS
The IMPRINT modiﬁcations to the CONSORT Checklist are
meant to improve the quality of reporting of trials of infertility
treatments, and ultimately to provide more complete data to
clinicians, patients, and public health about the effects of the
treatment for the infertility. The IMPRINT Statement, and this
Example and Explanation document, may also help in the
design of future studies, especially with its recommendation
to deﬁne both primary and secondary outcomes before trial
initiation and its plea to track all important beneﬁts and harms
to participants to the point of live birth. We have provided ex-
planations for the modiﬁcations and examples of what we
consider good reporting. We acknowledge that we set a high
standard with these modiﬁcations, such that there are few, or
possible no, published clinical trials that currently meet all of
these recommendations.Wehope that this documentwill result
in improvements in the reporting of infertility trials, whichwill
provide better and safer care of infertile patients.
As proponents of evidence-based medicine, we acknowl-
edge the efforts and success of the original CONSORT State-
ment and its many modiﬁcations. We note that IMPRINT is
an evolving document which we intend to revise over time
and modify as necessary. These recommendations, just as
with the CONSORT Statement, are not binding nor are they
a necessary precondition for publication of trials of infertility
treatments. There may be compelling reasons for not
complying with individual recommendations, but we feel
that these should be included in the reporting of the trial. If,
for example, live birth was not obtained or there was no
assessment of pregnancy complications, then it would be
optimal for the authors to acknowledge the decision not to
follow the reporting guidelines of IMPRINT, rather than
have reviewers, editors, readers, and subsequent data extrac-
tors question the omission.
We have continued tomeet regularly as a group tomodify
this document and to assess its implementation in reviewing
submitted infertility trials to our main journals. We plan to
track its impact on improving the reporting of beneﬁts and
harms of infertility trials. As critical comments appear and
new evidence emerges regarding reporting of infertility trials,
we are open to modifying this document.
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